VIVAZEN Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine, Reinforces Commitment to Safe Botanical Wellness and Consumer Transparency
VIVAZEN®, a leading botanical wellness company in the United States, has welcomed the recent decision by the U.S. Drug Enforcement Administration (DEA) to classify 7-hydroxymitragynine (7-OH) and three related synthetic compounds as Schedule I controlled substances. The company described the move as an important milestone for consumer protection, public health, and the integrity of the botanical wellness industry.
According to VIVAZEN, the DEA’s action establishes a clear regulatory distinction between dangerous laboratory-produced substances and naturally derived botanical products such as kratom. The decision follows growing concerns from federal health agencies regarding the safety profile of synthetic 7-OH compounds, which have been characterized by health authorities as potentially harmful and addictive.
By placing these substances into Schedule I, the DEA has acknowledged the significant public health risks associated with synthetic 7-OH while clarifying that naturally occurring kratom itself is not included in the scheduling action. VIVAZEN believes this distinction will help consumers better understand the differences between legitimate botanical wellness products and synthetic compounds that may be marketed in misleading ways.
Strengthening Consumer Protection
The company emphasized that the DEA’s decision represents a significant step toward improving transparency throughout the marketplace. According to VIVAZEN, consumers have increasingly faced confusion as synthetic products have entered the market while being promoted alongside natural botanical supplements.
Bryan Derr, Chief Operating Officer of VIVAZEN, said the company’s mission has always centered on providing safe, effective, and transparent botanical wellness products backed by responsible manufacturing practices.
He noted that the DEA’s scheduling action directly addresses the risks posed by synthetic 7-OH products, making the marketplace safer for consumers while reinforcing confidence in companies committed to responsible product development.
Derr explained that VIVAZEN has consistently prioritized innovation supported by quality standards, transparency, and consumer education. With federal regulators now distinguishing synthetic drugs from natural botanicals, responsible manufacturers can continue operating with greater clarity while reducing the likelihood that consumers will unknowingly purchase products containing potentially dangerous synthetic ingredients.
Clear Distinction Between Synthetic Drugs and Natural Botanicals
One of the most significant aspects of the DEA’s announcement, according to VIVAZEN, is the explicit clarification that the scheduling action is not intended to regulate natural kratom.
The company noted that federal agencies, including the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA), have specifically focused their concerns on synthetic 7-OH and related laboratory-created substances rather than naturally occurring botanical materials.
VIVAZEN believes this distinction is essential because synthetic compounds and natural botanical extracts differ substantially in origin, composition, and manufacturing processes.
By clearly separating synthetic drugs from botanical products, regulators are helping establish a more transparent environment where consumers can make informed purchasing decisions based on accurate product information.
Supporting Industry Integrity
For more than a decade, VIVAZEN has worked to advance standards within the botanical wellness sector by emphasizing responsible manufacturing, scientific validation, and product quality.
The company stated that manufacturers who introduce synthetic substances while marketing them as natural wellness products undermine both consumer trust and the reputation of the broader botanical industry.
According to VIVAZEN, responsible companies invest heavily in quality control, research, and regulatory compliance. When synthetic compounds are presented as botanical alternatives without adequate transparency, they create confusion for consumers and place compliant manufacturers at a competitive disadvantage.
The DEA’s recent scheduling decision helps address this issue by removing ambiguity surrounding synthetic 7-OH products and reinforcing the importance of accurate product labeling.
Commitment to Science-Based Botanical Wellness
VIVAZEN describes itself as a functional wellness company focused on developing botanical products manufactured under current Good Manufacturing Practice (GMP) standards.
The company states that its products are designed using carefully selected botanical ingredients supported by scientific research and manufactured through rigorous quality systems.
Its development philosophy emphasizes consistency, purity, and consumer safety throughout every stage of production.
Rather than relying on synthetic compounds that imitate natural ingredients, VIVAZEN says it remains committed to developing products derived from premium botanical sources while maintaining transparency about every ingredient included in its formulations.
Educating Consumers About Safe Product Selection
Alongside welcoming the DEA’s action, VIVAZEN is encouraging consumers to become more informed when selecting botanical wellness products.
The company believes education remains one of the strongest tools for improving public safety and helping consumers distinguish between legitimate botanical supplements and products containing synthetic substances.
Among the recommendations highlighted by the company are:
- Carefully review product labels to ensure ingredients are clearly identified. Authentic botanical kratom products should specifically list Mitragyna speciosa leaf extract, while all additional active ingredients should be fully disclosed.
- Follow product directions carefully and consult healthcare professionals before using botanical wellness products, particularly when combining them with medications or managing existing medical conditions.
- Purchase products from established manufacturers that demonstrate a commitment to quality, transparency, and responsible manufacturing practices.
According to VIVAZEN, these simple steps can help consumers make informed choices while reducing exposure to products that may contain undisclosed or synthetic ingredients.
Transparency Remains a Core Company Principle
The company emphasized that transparent labeling is one of the foundations of responsible product development.
Every active ingredient used in VIVAZEN formulations is clearly identified on product packaging, allowing retailers, healthcare professionals, regulators, and consumers to understand exactly what each product contains.
This approach reflects the company’s broader philosophy that transparency builds long-term consumer confidence while supporting informed decision-making.
VIVAZEN believes that complete ingredient disclosure should become the standard throughout the botanical wellness industry.
Rigorous Quality Assurance Standards
Beyond transparent labeling, VIVAZEN continues to emphasize comprehensive quality assurance throughout its manufacturing operations.
Each product undergoes independent third-party laboratory testing to verify ingredient identity, purity, potency, and compliance with the company’s internal quality specifications.
These testing procedures are intended to ensure that consumers receive products meeting consistent manufacturing standards while minimizing the risk of contamination or inaccurate labeling.
The company notes that maintaining strict quality controls has become increasingly important as consumers seek trusted brands in a rapidly evolving botanical wellness marketplace.
Building Confidence in Botanical Products
VIVAZEN believes the DEA’s scheduling decision represents more than a regulatory action—it also supports the long-term credibility of responsible botanical manufacturers.
By distinguishing laboratory-created synthetic compounds from natural botanical products, regulators are helping preserve confidence in companies that invest in scientific validation, manufacturing quality, and consumer education.
The company expects the decision to encourage greater transparency across the industry while helping responsible businesses continue developing botanical wellness products that meet evolving consumer expectations.
As the regulatory landscape continues to evolve, VIVAZEN says it will remain focused on advancing botanical wellness through science-based product development, responsible manufacturing, and consumer education.
The company views the DEA’s classification of synthetic 7-OH as an important step toward improving marketplace integrity while reinforcing the distinction between potentially harmful synthetic drugs and responsibly manufactured botanical products.
Moving forward, VIVAZEN plans to continue supporting initiatives that promote transparency, strengthen quality standards, and improve consumer understanding of botanical wellness products. Through ongoing investment in research, third-party testing, GMP manufacturing, and educational outreach, the company aims to help ensure that consumers have access to safe, clearly labeled, and high-quality botanical solutions that align with responsible wellness practices.
About VIVAZEN®
For over a decade, VIVAZEN® has delivered trusted, high-quality botanical supplements that provide people with functional wellness without compromise. Grounded in centuries of wellness practices and backed by modern innovation, VIVAZEN® products offer functional, feel-good alternatives for those who want to live — and feel — on their own terms. Join the millions who trust VIVAZEN® to Feel Great™ naturally
